SOURCE: Corbus Pharmaceuticals
NORWOOD, MA--(Marketwired - Sep 4, 2014) - Corbus Pharmaceuticals Holdings, Inc., an emerging drug development company focused on the development and commercialization of its lead product candidate, Resunab™, for the treatment of rare, life-threatening inflammatory diseases, announced today that the Company's Chief Executive Officer, Yuval Cohen, Ph.D., will be presenting a corporate overview and a review of the clinical development plans for its lead product candidate, Resunab, in the treatment of Systemic Sclerosis and Cystic Fibrosis. The two upcoming investor conferences are:
Event: Rodman & Renshaw 16th Annual Global Investment Conference
Date: Tuesday, September 9, 2014
Time: 1:15 p.m. Eastern Time
Location: New York Palace Hotel, New York, NY
Event: Aegis Capital Healthcare and Technology Conference
Date: Thursday, September 11, 2014
Time: 8:30 a.m. Pacific Time (11:30 p.m. Eastern Time)
Location: Encore at Wynn, Las Vegas, NV
Live audio webcasts of both the Rodman & Renshaw presentation and the Aegis Capital presentation will be available on the Company's website (www.corbuspharma.com) in the Investor Relations section (http://www.corbuspharma.com/investorrelations.html). The webcast replays will be available approximately two hours after each presentation ends and will be accessible for one month.
Resunab™ is a novel synthetic oral drug with unique anti-inflammatory and anti-fibrotic activity. Pre-clinical and Phase 1 studies have shown Resunab to have a favorable safety profile coupled with promising potency in pre-clinical models. Resunab binds to the CB2 receptor of immune cells and triggers a process known as "inflammatory resolution," in effect turning chronic inflammation "off."
About Corbus Pharmaceuticals
Corbus Pharmaceuticals is a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare life-threatening inflammatory-fibrotic diseases with clear unmet medical needs. Our lead product candidate Resunab is a novel oral anti-inflammatory drug scheduled to commence Phase 2a clinical trials for the treatment of cystic fibrosis and diffuse scleroderma in 2015. For more information, please visit www.CorbusPharma.com.
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors, including the possibility of unfavorable results from studies and clinical trials involving Resunab or other product candidates. Corbus Pharmaceuticals Holdings, Inc. also faces risks related to its ability to enroll patients in studies and may need to modify or delay these studies. As a result, Resunab may never be successfully commercialized. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. All forward-looking statements are based on information currently available to Corbus Pharmaceuticals Holdings, Inc. and the Company assumes no obligation to update any such forward-looking statements.